Syndax Pharmaceuticals, Inc. (SNDX)
Largest Insider Buys in Sector
SNDX Stock Price History Chart
SNDX Stock Performance
About Syndax Pharmaceuticals, Inc.
Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin 1 mutant acute myeloid leukemia (NPM1c AML); and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic …
Insider Activity of Syndax Pharmaceuticals, Inc.
Over the last 12 months, insiders at Syndax Pharmaceuticals, Inc. have bought $25,037 and sold $0 worth of Syndax Pharmaceuticals, Inc. stock.
On average, over the past 5 years, insiders at Syndax Pharmaceuticals, Inc. have bought $211,551 and sold $12.76M worth of stock each year.
Highest buying activity among insiders over the last 12 months: Goldan Keith A. (Chief Financial Officer) — $50,075.
The last purchase of 1,250 shares for transaction amount of $25,037 was made by Goldan Keith A. (Chief Financial Officer) on 2024‑06‑14.
List of Insider Buy and Sell Transactions, Syndax Pharmaceuticals, Inc.
| 2024-06-14 | Chief Financial Officer | 1,250 0.0015% | $20.03 | $25,037 | -2.26% | |||
| 2023-08-09 | Sale | director | 52,855 0.0754% | $18.27 | $965,402 | +7.80% | ||
| 2023-08-02 | Sale | director | 83,000 0.12% | $20.46 | $1.7M | -1.44% | ||
| 2023-07-10 | Sale | director | 52,855 0.0766% | $20.40 | $1.08M | -0.02% | ||
| 2023-06-13 | Sale | Chief Financial Officer | 577 0.0008% | $22.31 | $12,873 | -8.20% | ||
| 2023-06-09 | Sale | director | 52,855 0.0762% | $21.18 | $1.12M | -2.88% | ||
| 2023-05-09 | Sale | director | 52,855 0.0754% | $21.41 | $1.13M | -3.89% | ||
| 2023-04-10 | Sale | director | 52,855 0.0768% | $19.53 | $1.03M | +5.79% | ||
| 2023-03-13 | Sale | 52,854 0.0765% | $22.53 | $1.19M | -9.01% | |||
| 2023-02-15 | Sale | 17,428 0.025% | $25.84 | $450,404 | -21.55% | |||
| 2023-02-06 | Sale | 52,854 0.077% | $26.83 | $1.42M | -23.14% | |||
| 2023-02-06 | Sale | 5,959 0.0089% | $27.64 | $164,697 | -23.14% | |||
| 2023-02-01 | Sale | 69 <0.0001% | $28.43 | $1,962 | -29.64% | |||
| 2023-01-13 | Sale | director | 5,000 0.0074% | $27.00 | $135,000 | -22.23% | ||
| 2022-12-02 | Sale | Chief Scientific Officer | 17,200 0.0272% | $25.05 | $430,936 | -16.75% | ||
| 2022-10-06 | Sale | director | 20,782 0.0325% | $25.90 | $538,273 | -17.82% | ||
| 2022-10-06 | Sale | Chief Executive Officer | 16,231 0.0248% | $25.29 | $410,508 | -17.82% | ||
| 2022-10-04 | Sale | director | 137 0.0002% | $25.00 | $3,425 | |||
| 2022-10-04 | Sale | Chief Executive Officer | 1,280 0.002% | $25.02 | $32,026 | |||
| 2022-09-15 | Sale | director | 66,840 0.1085% | $24.20 | $1.62M | -11.15% |
Insider Historical Profitability
| Goldan Keith A. | Chief Financial Officer | 52623 0.0616% | $16.08 | 1 | 1 | |
| ROYSTON IVOR | director | 750545 0.8793% | $16.08 | 1 | 0 | <0.0001% |
| Podlesak Dennis | director | 75763 0.0888% | $16.08 | 1 | 1 | +23.96% |
| Morrison Briggs | director | 17836 0.0209% | $16.08 | 4 | 18 | +43.88% |
| Meyers Michael L. | SVP, Chief Medical Officer | 15666 0.0184% | $16.08 | 3 | 0 | +40.96% |
Institutional Investor Ownership
| BlackRock | $179.75M | 8.89 | 7.55M | +7.65% | +$12.78M | <0.01 | |
| Wellington Management Company | $176.99M | 8.75 | 7.44M | -1.96% | -$3.54M | 0.03 | |
| Kynam Capital Management Lp | $134.71M | 6.66 | 5.66M | 0% | +$0 | 1.7 | |
| The Vanguard Group | $117.26M | 5.8 | 4.93M | +13.65% | +$14.08M | <0.01 | |
| State Street | $114.71M | 5.67 | 4.82M | -3.92% | -$4.68M | 0.01 |